Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Marschner

Showing results (71-80 of 89) with videos related to

Pageof 9
Sort By:
JNCI Cancer Spectrum|June 2, 2025
INTEGRATE pooled phase 2/3 results are robust to postprogression switching and the winner's curseYu Yang Soon, Katrin Sjoquist, Ian C Marschner, et al.
The Journal of Infectious Diseases|February 1, 1995
Lombok Hepatitis B Model Immunization Project: toward universal infant hepatitis B immunization in IndonesiaT A Ruff, D M Gertig, B F Otto, et al.
Circulation|March 13, 2002
Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?R John Simes, Ian C Marschner, David Hunt, et al.
European Journal of Endocrinology|July 5, 2023
Mediation analysis of the testosterone treatment effect to prevent type 2 diabetes in the Testosterone for Prevention of Type 2 Diabetes Mellitus trialKristy P Robledo, Ian C Marschner, David J Handelsman, et al.
Respirology (Carlton, Vic.)|October 7, 2025
Inhaled Ciclesonide for Community-Based COVID-19: A Placebo-Controlled Randomised TrialPeter Wark, Ian C Marschner, Owen Hutchings, et al.
The New England Journal of Medicine|October 29, 1998
Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 TeamD V Havlir, I C Marschner, M S Hirsch, et al.
AIDS (London, England)|September 13, 2000
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370D R Kuritzkes, R L Bassett, V A Johnson, et al.
American Heart Journal|June 24, 2010
Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trialR John Simes, Rachel L O'Connell, Philip E Aylward, et al.
Journal of the American Heart Association|October 25, 2013
Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease studyHarvey D White, John Simes, Ralph A H Stewart, et al.
The Journal of Infectious Diseases|January 7, 1998
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapyI C Marschner, A C Collier, R W Coombs, et al.
Pageof 9

Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
JNCI Cancer Spectrum|June 2, 2025
INTEGRATE pooled phase 2/3 results are robust to postprogression switching and the winner's curseYu Yang Soon, Katrin Sjoquist, Ian C Marschner, et al.
The Journal of Infectious Diseases|February 1, 1995
Lombok Hepatitis B Model Immunization Project: toward universal infant hepatitis B immunization in IndonesiaT A Ruff, D M Gertig, B F Otto, et al.
Circulation|March 13, 2002
Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?R John Simes, Ian C Marschner, David Hunt, et al.
European Journal of Endocrinology|July 5, 2023
Mediation analysis of the testosterone treatment effect to prevent type 2 diabetes in the Testosterone for Prevention of Type 2 Diabetes Mellitus trialKristy P Robledo, Ian C Marschner, David J Handelsman, et al.
Respirology (Carlton, Vic.)|October 7, 2025
Inhaled Ciclesonide for Community-Based COVID-19: A Placebo-Controlled Randomised TrialPeter Wark, Ian C Marschner, Owen Hutchings, et al.
The New England Journal of Medicine|October 29, 1998
Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 TeamD V Havlir, I C Marschner, M S Hirsch, et al.
AIDS (London, England)|September 13, 2000
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370D R Kuritzkes, R L Bassett, V A Johnson, et al.
American Heart Journal|June 24, 2010
Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trialR John Simes, Rachel L O'Connell, Philip E Aylward, et al.
Journal of the American Heart Association|October 25, 2013
Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease studyHarvey D White, John Simes, Ralph A H Stewart, et al.
The Journal of Infectious Diseases|January 7, 1998
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapyI C Marschner, A C Collier, R W Coombs, et al.
Pageof 9